Replies to post #6299 on Aurinia Pharmaceuticals Inc (AUPH)

[nferna]

I have a quick follow up thought on that:

My fear (irrational, I hope) is that, with a healthier study population, the comparator group might perform better in Ph3 than they did in Ph2.

It would be interesting to see an analysis of the Ph2 data excluding the questionable sites.